As you know, research on PCa is mostly performed on mouse models that attempt to replicate the PCa tumor progression in humans. This could be a major breakthrough in discovering that a gene called Myc “drives” metastasis – a different pathway than the one driving primary tumors.
1) A team of researchers led by Associate Professor Lloyd Trotman has developed a new method to rapidly create much better mouse models. As his team explains in Cancer Discovery, to develop the new model, called RapidCaP, they directly induced gene mutations within the prostate When they put the new model to work, the team was excited to discover that a gene called Myc “drives” metastasis – a different pathway than the one driving primary tumors. They treated the mice with a newly discovered drug called JQ1 that lowers the amount of Myc in cells. This shrank the metastases, suggesting, says Trotman, “that our model provides an excellent test-bed for developing new approaches to cure the type of prostate cancer that now is incurable.”
2) PMSA ADC Enters Phase II Clinical Trials in Men With mCRPC, (castration-resistant prostate cancer)
PSMA ADC consists of a fully human monoclonal antibody, which binds PSMA, linked to a cytotoxic drug, monomethyl auristatin E (MMAE), which inhibits cell proliferation by disrupting the cellular “backbone” required for replication. The antibody-drug conjugate is designed to be absorbed by the cell and release active anti-cancer drug, thereby destroying the malignant cell.
Please take an active part in helping us at The New Denver Men’s Club uncover new and potential breakthrough articles on prostate cancer research by emailing them to Craig @ email@example.com
“Make Every Day Count” !
The New Denver Men’s Club
“Men Fighting Cancer To Win”